Objective: To explore the role of PA and PAIs in ovarian tumor growth,invasion and metastasis,and to analyze the relationship between the expression of PA or PAI and clinical-pathologic parameters and overall survive in ovarian cancer, to evaluated the effects of matrine on the growth of SKOV3 in vitro. Methods: Reverse-transcriptase polymerase chain reaction were used to detect the expression of PA and PAIs in 43 ovarian carcinomas ,20 cases of benign tumors and 20 cases of normal controls, meanwhile we detected uPA and PAI-1 protein expression by IHC from another 40 patients with ovarian carcinomas, 20 cases of benign tumor and 20 cases of normal controls. The effect of matrine on the growth of SKOV3 in vivo were also investigate by MTT and cell counting. The expression of uPA and PAI-1 of SKOV3 were also investigate by IHC. Results: Firstly, the expression of uPAmRNA were significantly higher than that in benign tumor and normal control(74.42%,35% and 25%,respectively,P<0.05),the expression of PAI-1mRNA were also significantly higher than that in benign tumor and normal control(65.12%,15%and 15%,respectively,P<0.05); Secondly, the protein expression of uPA were significantly higher than that in benign tumor and normal control(52.50%,20% and15 %,respectively,P<0.05), the protein expression of PAI-1 were significantly higher than that in benign tumor and normal control(67.50%,30% and25%,respectively,P<0.05); Thirdly,there was no significantly association between expression levels of uPA and PAI-1 mRNA and its histopathologic type , ascitic volume and liver metastasis; but they showed that there was significant difference with differentiated grade, clinical stage as well as residual tumor volume in ovarian carcinomas. The positive expression rate of uPAmRNA in â…¢~â…£ phase (90%)was significantly higher than inâ… ~â…¡phase(38.46%, P<0.05)ï¼›the positive expression rate of PAI-1mRNA in â…¢~â…£ phase (76.67%)was significantly higher than inâ… ~â…¡phase(38.46%, P<0.05).They were higher in cases with lymph node metastasis(100%,78.57%respectively)than that without(26.67%,40% respectively, P<0.05). The positive expression rate of uPAmRNA with omentum involvement was higher than that in patients without omentum involvement( P<0.05)ï¼›There is no relationship between the expression of PAI-1mRNA and omentum involvement.The levels of uPAmRNA, PAI-1mRNA in patients with residual diseases >2cm (95.24%,90.48% respectively)than that in those have none(63.64%,4.55% respectively,P<0.05).Fourthly, no significantly association was evident between protein expression levels of uPA and PAI-1 and its histopathologic type , ascitic volume and lymph node metastasis; but they show significant difference with differentiated grade, clinical stage as well as residual tumor volume in ovarian carcinomas. The positive expression rate of uPA protein in â…¢~â…£ phase (68%)was significantly higher than inâ… ~â…¡phase(26.67%, P<0.05)ï¼›the positive expression rate of PAI-1 protein in â…¢~â…£ phase (80%)was significantly higher than inâ… ~â…¡phase(46.67%, P<0.05). The positive expression rate of uPA protein with omentum involvement was higher than that in patients without omentum involvement(92.86% and 30.77% respectly P<0.05)ï¼›there is no relationship between PAI-1 protein and omentum involvement. The positive expression rate of uPA protein with liver metastasis was higher than that in patients without liver metastasis (78.57% and 38.46% respectly P<0.05)ï¼›there is no relationship between PAI-1 protein and liver metastasis. The protein levels of PAI-1 in patients with residual diseases >2cm (93.75%)than that in those have none(50%,P<0.05);no significantly association was evident between expression levels of uPA protein and residual diseases. Fifthly, uPA and PAI-1 expresstion had a poorly overall survive in ovarian carcinomas; the patients with positive expression of uPA and PAI-1 had a poorly overall survive in ovarian carcinomas. Cox regression showed that uPA and PAI-1 were in independent prognostic factors affecting survival and they had close negative c...
|